CN110179922A - A kind of the She nationality, distributed over Fujian, Zhejiang, Jiangxi and Guangdong's medicine prescription for the treatment of hypertension syndrome of blood stasis - Google Patents

A kind of the She nationality, distributed over Fujian, Zhejiang, Jiangxi and Guangdong's medicine prescription for the treatment of hypertension syndrome of blood stasis Download PDF

Info

Publication number
CN110179922A
CN110179922A CN201910481381.2A CN201910481381A CN110179922A CN 110179922 A CN110179922 A CN 110179922A CN 201910481381 A CN201910481381 A CN 201910481381A CN 110179922 A CN110179922 A CN 110179922A
Authority
CN
China
Prior art keywords
parts
jiangxi
nationality
zhejiang
guangdong
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
CN201910481381.2A
Other languages
Chinese (zh)
Other versions
CN110179922B (en
Inventor
陈礼平
张晓芹
王华强
王娜妮
林娜
潘铨
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
LISHUI HOSPITAL OF TRADITIONAL CHINESE MEDICINE
Original Assignee
LISHUI HOSPITAL OF TRADITIONAL CHINESE MEDICINE
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by LISHUI HOSPITAL OF TRADITIONAL CHINESE MEDICINE filed Critical LISHUI HOSPITAL OF TRADITIONAL CHINESE MEDICINE
Priority to CN201910481381.2A priority Critical patent/CN110179922B/en
Publication of CN110179922A publication Critical patent/CN110179922A/en
Application granted granted Critical
Publication of CN110179922B publication Critical patent/CN110179922B/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/56—Materials from animals other than mammals
    • A61K35/62—Leeches; Worms, e.g. cestodes, tapeworms, nematodes, roundworms, earth worms, ascarids, filarias, hookworms, trichinella or taenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/21—Amaranthaceae (Amaranth family), e.g. pigweed, rockwort or globe amaranth
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/23—Apiaceae or Umbelliferae (Carrot family), e.g. dill, chervil, coriander or cumin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
    • A61K36/481—Astragalus (milkvetch)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
    • A61K36/488—Pueraria (kudzu)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/53—Lamiaceae or Labiatae (Mint family), e.g. thyme, rosemary or lavender
    • A61K36/533—Leonurus (motherwort)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/53—Lamiaceae or Labiatae (Mint family), e.g. thyme, rosemary or lavender
    • A61K36/537—Salvia (sage)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/65—Paeoniaceae (Peony family), e.g. Chinese peony
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/71—Ranunculaceae (Buttercup family), e.g. larkspur, hepatica, hydrastis, columbine or goldenseal
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/73—Rosaceae (Rose family), e.g. strawberry, chokeberry, blackberry, pear or firethorn
    • A61K36/734—Crataegus (hawthorn)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/74—Rubiaceae (Madder family)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/88—Liliopsida (monocotyledons)
    • A61K36/888—Araceae (Arum family), e.g. caladium, calla lily or skunk cabbage
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/88—Liliopsida (monocotyledons)
    • A61K36/896—Liliaceae (Lily family), e.g. daylily, plantain lily, Hyacinth or narcissus
    • A61K36/8969—Polygonatum (Solomon's seal)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/88—Liliopsida (monocotyledons)
    • A61K36/898—Orchidaceae (Orchid family)
    • A61K36/8988—Gastrodia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Botany (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Medical Informatics (AREA)
  • Biotechnology (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Cardiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

The invention discloses a kind of for hypertension syndrome of blood stasis with the Chinese prescription of medicine containing the She nationality, distributed over Fujian, Zhejiang, Jiangxi and Guangdong of target organ damage patient, it is characterized in that, the Chinese prescription of medicine containing the She nationality, distributed over Fujian, Zhejiang, Jiangxi and Guangdong for hypertension syndrome of blood stasis companion target organ damage patient includes: herbal tea 5-15 parts of food, 10-15 parts of loud, high-pitched sound dog Lu, 25-35 parts of Radix Salviae Miltiorrhizae, 10-20 parts of cortex moutan, motherwort 25-35 parts dry, 10-15 parts of radix paeoniae rubra, 6-13 parts of Rhizoma Gastrodiae, 10-20 parts of uncaria, 10-20 parts of rhizoma acori graminei, 10-20 parts of radix cyathulae, scalds 1-2 parts of leech powder by weight；1. person adds with ventricular hypertrophy: 15-25 parts of Radix Astragali, 10-20 parts of raw hawthorn；2. person adds with renal damage: 10-20 parts of RHIZOMA POLYGONATI PREPARATA, 25-35 parts of centella；3. impairer adds with arteria carotis: 25-35 parts of pueraria lobata.

Description

A kind of the She nationality, distributed over Fujian, Zhejiang, Jiangxi and Guangdong's medicine prescription for the treatment of hypertension syndrome of blood stasis
Technical field
The invention belongs to drug field, in particular to a kind of the She nationality, distributed over Fujian, Zhejiang, Jiangxi and Guangdong's medicine for hypertension syndrome of blood stasis companion target organ damage patient Prescription and preparation method thereof.
Background technique
High blood pressure can lead to the damage of multiple target organs, have studies have shown that high blood pressure can be by pressure load, nerve The number of mechanisms such as body fluid, Cellular Signaling Transduction Mediated and inherent cause act on cardiac muscle cell, cause cardiac myocyte hypertrophy, fibrosis With the change of extracellular matrix, and then cause ventricular hypertrophy.Ventricular hypertrophy reduces the compliance of heart, causes diastolic function limited Weak pulse loop structure of coming of age changes and dysfunction, this significantly increases the diseases such as coronary heart disease, heart failure and arrhythmia cordis Occurrence risk.High blood pressure also causes kidney to be in high perfusion state, this is to glomerulus hair while increasing myocardial muscle load Thin vascular endothelial cell and visceral layer epithelial cell are a kind of damages, cause its malfunction, and a small amount of protein is caused to leak out, and are caused Microdose urine protein, microdose urine protein are albuminuria indexs；
High blood pressure onset is slow, and the course of disease is touching, prolonged illness must the stasis of blood, syndrome of blood stasis occupies quite high ratio in high blood pressure Example；In the prior art, there is no any notes about the Chinese medicine preparation that can be used for hypertension syndrome of blood stasis companion target organ damage person It carries.
Summary of the invention
The object of the present invention is to provide a kind of for hypertension syndrome of blood stasis with the Chinese medicine group of medicine containing the She nationality, distributed over Fujian, Zhejiang, Jiangxi and Guangdong of target organ damage patient Side, and the production method of the Chinese medicine preparation is provided, to solve the problems mentioned in the above background technology.
To achieve the above object, the invention provides the following technical scheme:
A kind of Chinese prescription of medicine containing the She nationality, distributed over Fujian, Zhejiang, Jiangxi and Guangdong for hypertension syndrome of blood stasis companion target organ damage patient includes that food is cool by weight 5-15 parts of tea, 10-15 parts of loud, high-pitched sound dog Lu, 25-35 parts of Radix Salviae Miltiorrhizae, 10-20 parts of cortex moutan, motherwort 25-35 parts dry, 10-15 parts of radix paeoniae rubra, 6-13 parts of Rhizoma Gastrodiae, 10-20 parts of rhizoma acori graminei, 10-20 parts of radix cyathulae, scalds 1-2 parts of leech powder at 10-20 parts of uncaria；
1. person adds with ventricular hypertrophy: 15-25 parts of Radix Astragali, 10-20 parts of raw hawthorn；
2. person adds with renal damage: 10-20 parts of RHIZOMA POLYGONATI PREPARATA, 25-35 parts of centella；
3. impairer adds with arteria carotis: 25-35 parts of pueraria lobata.
The Chinese prescription of medicine containing the She nationality, distributed over Fujian, Zhejiang, Jiangxi and Guangdong for hypertension syndrome of blood stasis companion target organ damage patient includes food herbal tea (willow by weight Leaf wax plum) 10 parts, 12 parts of loud, high-pitched sound dog Lu (harvest), 30 parts of Radix Salviae Miltiorrhizae, 15 parts of cortex moutan, 30 parts of dry motherwort, 12 parts of radix paeoniae rubra, Rhizoma Gastrodiae 9 Part, 15 parts of radix cyathulae, scalds 1.5 parts of leech powder at 15 parts of uncaria, 15 parts of rhizoma acori graminei.
1. person adds with ventricular hypertrophy: 20 parts of Radix Astragali, 15 parts of raw hawthorn；
2. person adds with renal damage: 15 parts of RHIZOMA POLYGONATI PREPARATA, 30 parts of centella；
3. impairer adds with arteria carotis: 30 parts of pueraria lobata.
A kind of preparation method of the Chinese prescription of medicine containing the She nationality, distributed over Fujian, Zhejiang, Jiangxi and Guangdong for hypertension syndrome of blood stasis companion target organ damage patient, The following steps are included:
(1) by weight, by 10-15 parts of loud, high-pitched sound dog Lu, 25-35 parts of Radix Salviae Miltiorrhizae, 10-20 parts of cortex moutan, dry motherwort 25-35 Part, 10-15 parts of radix paeoniae rubra, 6-13 parts of Rhizoma Gastrodiae, 10-20 parts of radix cyathulae；
1. person adds with ventricular hypertrophy: 15-25 parts of Radix Astragali, 10-20 parts of raw hawthorn；
2. person adds with renal damage: 10-20 parts of RHIZOMA POLYGONATI PREPARATA, 25-35 parts of centella；
3. impairer adds with arteria carotis: 25-35 parts of pueraria lobata；
The water that 10-15 times of weight is added decocts 1-2h, filtering, and medical fluid is retained.
(2) 4-6 times is continuously added in the dregs of a decoction of step (1) and measures water, and food herbal tea 5-15 parts, uncaria 10-20 is added in decocting 1h Part, 10-20 parts of rhizoma acori graminei continue to decoct 20 minutes, and filtering, medical fluid merges with step (1) Chinese medicine liquid；
(3) medical fluid of step (2) carries out being concentrated into concentrate relative density being 1.20-1.40, pH value 4.0-6.0；
(4) 1-2 parts of leech powder is scalded, is merged with step (3) Chinese medicine liquid, is obtained described for hypertension syndrome of blood stasis companion's target organ damage The Chinese medicine liquid of the Chinese prescription of medicine containing the She nationality, distributed over Fujian, Zhejiang, Jiangxi and Guangdong of evil patient.
A kind of preparation method of the Chinese prescription of medicine containing the She nationality, distributed over Fujian, Zhejiang, Jiangxi and Guangdong for hypertension syndrome of blood stasis companion target organ damage patient, The following steps are included:
(1) by weight, by 12 parts of loud, high-pitched sound dog Lu, 30 parts of Radix Salviae Miltiorrhizae, 15 parts of cortex moutan, 30 parts of dry motherwort, 12 parts of radix paeoniae rubra, 9 parts of Rhizoma Gastrodiae, 15 parts of radix cyathulae；
1. person adds with ventricular hypertrophy: 20 parts of Radix Astragali, 15 parts of raw hawthorn；
2. person adds with renal damage: 15 parts of RHIZOMA POLYGONATI PREPARATA, 30 parts of centella；
3. impairer adds with arteria carotis: 30 parts of pueraria lobata；
The water that 10-15 times of weight is added decocts 1-2h, filtering, and medical fluid is retained.
(2) 4-6 times is continuously added in the dregs of a decoction of step (1) and measures water, and food 10 parts of herbal tea, 15 parts of uncaria, stone is added in decocting 1h 15 parts of calamus, continue to decoct 20 minutes, filtering, medical fluid merges with step (1) Chinese medicine liquid；
(3) medical fluid of step (2) carries out being concentrated into concentrate relative density being 1.20-1.40, pH value 4.0-6.0；
(4) 1-2 parts of leech powder is scalded, is merged with step (3) Chinese medicine liquid, is obtained described for hypertension syndrome of blood stasis companion's target organ damage The preparation of the Chinese prescription of medicine containing the She nationality, distributed over Fujian, Zhejiang, Jiangxi and Guangdong of evil patient.
The water that 12 times of weight are added in the step (1) decocts 1h.
The water of 4 times of weight is added in the step (2).
Concentrate relative density is 1.03 in the step (3).
PH value is 5.1 in the step (3).
The advantageous effects of the present invention compared with the existing technology are,
First, the She nationality, distributed over Fujian, Zhejiang, Jiangxi and Guangdong's medicine prescription reduces blood pressure to hypertension syndrome of blood stasis with target organ damage patient, with systolic pressure It reduces obvious.
Second, the She nationality, distributed over Fujian, Zhejiang, Jiangxi and Guangdong's medicine prescription has adjusting and guarantor with target organ damage vascular endothelial cell function to hypertension syndrome of blood stasis Shield effect, shows as elevation of NO, 6-Keto-PGF-1 alpha levels, and it is horizontal to reduce ET-1 and TXB2.
Third, the She nationality, distributed over Fujian, Zhejiang, Jiangxi and Guangdong's medicine prescription therapeutic hypertension syndrome of blood stasis have preferable safety with target organ damage patient.
Detailed description of the invention
The Human umbilical vein endothelial cells of Fig. 1 secondary culture.
Specific embodiment
With reference to the accompanying drawing and specific implementation the present invention is further illustrated.
A kind of Chinese prescription of medicine containing the She nationality, distributed over Fujian, Zhejiang, Jiangxi and Guangdong for hypertension syndrome of blood stasis companion target organ damage patient includes that food is cool by weight 5-15 parts of tea, 10-15 parts of loud, high-pitched sound dog Lu, 25-35 parts of g of Radix Salviae Miltiorrhizae, 10-20 parts of g of cortex moutan, motherwort 25-35 parts dry, radix paeoniae rubra 10-15 Part, 10-20 parts of radix cyathulae, scalds 1-2 parts of leech powder at 6-13 parts of Rhizoma Gastrodiae, 10-20 parts of uncaria, 10-20 parts of rhizoma acori graminei；
1. person adds with ventricular hypertrophy: 15-25 parts of Radix Astragali, 10-20 parts of raw hawthorn；
2. person adds with renal damage: 10-20 parts of RHIZOMA POLYGONATI PREPARATA, 25-35 parts of centella；
3. impairer adds with arteria carotis: 25-35 parts of pueraria lobata.
The Chinese prescription of medicine containing the She nationality, distributed over Fujian, Zhejiang, Jiangxi and Guangdong for hypertension syndrome of blood stasis companion target organ damage patient includes food herbal tea (willow by weight Leaf wax plum) 10 parts, 12 parts of loud, high-pitched sound dog Lu (harvest), 30 parts of Radix Salviae Miltiorrhizae, 15 parts of cortex moutan, 30 parts of dry motherwort, 12 parts of radix paeoniae rubra, Rhizoma Gastrodiae 9 Part, 15 parts of radix cyathulae, scalds 1.5 parts of leech powder at 15 parts of uncaria, 15 parts of rhizoma acori graminei.
1. person adds with ventricular hypertrophy: 20 parts of Radix Astragali, 15 parts of raw hawthorn；
2. person adds with renal damage: 15 parts of RHIZOMA POLYGONATI PREPARATA, 30 parts of centella；
3. impairer adds with arteria carotis: 30 parts of pueraria lobata.
A kind of preparation method of the Chinese prescription of medicine containing the She nationality, distributed over Fujian, Zhejiang, Jiangxi and Guangdong for hypertension syndrome of blood stasis companion target organ damage patient, The following steps are included:
(1) by weight, by 10-15 parts of loud, high-pitched sound dog Lu, 25-35 parts of Radix Salviae Miltiorrhizae, 10-20 parts of cortex moutan, dry motherwort 25-35 Part, 10-15 parts of radix paeoniae rubra, 6-13 parts of Rhizoma Gastrodiae, 10-20 parts of radix cyathulae；
1. person adds with ventricular hypertrophy: 15-25 parts of Radix Astragali, 10-20 parts of raw hawthorn；
2. person adds with renal damage: 10-20 parts of RHIZOMA POLYGONATI PREPARATA, 25-35 parts of centella；
3. impairer adds with arteria carotis: 25-35 parts of pueraria lobata；
The water that 10-15 times of weight is added decocts 1-2h, filtering, and medical fluid is retained.
(2) 4-6 times is continuously added in the dregs of a decoction of step (1) and measures water, and food herbal tea 5-15 parts, uncaria 10-20 is added in decocting 1h Part, 10-20 parts of rhizoma acori graminei continue to decoct 20 minutes, and filtering, medical fluid merges with step (1) Chinese medicine liquid；
(3) medical fluid of step (2) carries out being concentrated into concentrate relative density being 1.20-1.40, pH value 4.0-6.0；
(4) 1-2 parts of leech powder is scalded, is merged with step (3) Chinese medicine liquid, is obtained described for hypertension syndrome of blood stasis companion's target organ damage The preparation of the Chinese prescription of medicine containing the She nationality, distributed over Fujian, Zhejiang, Jiangxi and Guangdong of evil patient.
It is prepared by a kind of preparation for hypertension syndrome of blood stasis with the Chinese prescription of medicine containing the She nationality, distributed over Fujian, Zhejiang, Jiangxi and Guangdong of target organ damage patient Method, comprising the following steps:
(1) by weight, by 12 parts of loud, high-pitched sound dog Lu, 30 parts of Radix Salviae Miltiorrhizae, 15 parts of cortex moutan, 30 parts of dry motherwort, 12 parts of radix paeoniae rubra, 9 parts of Rhizoma Gastrodiae, 15 parts of radix cyathulae；
1. person adds with ventricular hypertrophy: 20 parts of Radix Astragali, 15 parts of raw hawthorn；
2. person adds with renal damage: 15 parts of RHIZOMA POLYGONATI PREPARATA, 30 parts of centella；
3. impairer adds with arteria carotis: 30 parts of pueraria lobata；
The water that 10-15 times of weight is added decocts 1-2h, filtering, and medical fluid is retained.
(2) 4-6 times is continuously added in the dregs of a decoction of step (1) and measures water, and food 10 parts of herbal tea, 15 parts of uncaria, stone is added in decocting 1h 15 parts of calamus, continue to decoct 20 minutes, filtering, medical fluid merges with step (1) Chinese medicine liquid；
(3) medical fluid of step (2) carries out being concentrated into concentrate relative density being 1.20-1.40, pH value 4.0-6.0；
(4) 1-2 parts of leech powder is scalded, is merged with step (3) Chinese medicine liquid, is obtained described for hypertension syndrome of blood stasis companion's target organ damage The preparation of the Chinese prescription of medicine containing the She nationality, distributed over Fujian, Zhejiang, Jiangxi and Guangdong of evil patient.
The water that 12 times of weight are added in the step (1) decocts 1h.
The water of 4 times of weight is added in the step (2).
Concentrate relative density is 1.03 in the step (3).
PH value is 5.1 in the step (3).
Clinical laboratory data is as follows:
One, Study on extraction
1. the selection of medicinal material granularity
Extraction preliminary experiment has been carried out to medicinal material, weigh medicine materical crude slice by optimization formula respectively and has crossed the powder of 60 meshes.According to excellent It is prepared by the preparation process of choosing.Extracting solution merges, and is concentrated under reduced pressure into right amount, is transferred to 100ml measuring bottle, lets cool, add water constant volume To scale, shake up.(the rate of extract measurement: precision measures medical fluid 25ml, sets for filtering situation, measurement the rate of extract after observation decoction Drying is into the evaporating dish of constant weight, 3 hours dry in 105 DEG C after being evaporated in water-bath, sets cooling 30 minutes in drier, fast The accurately weighed weight of speed, calculates the rate of extract.) result see the table below.
1 granularity of table investigates result
Sample granularity Filter situation The rate of extract (%)
Medicine materical crude slice It is easier to filter 16.8
Coarse powder It is more difficult to filter 17.3
As a result: the granularity investigation result of medicine materical crude slice, coarse powder: the no significant difference in terms of the rate of extract, it is contemplated that actual production, choosing Medicine materical crude slice is selected to feed intake.
2. the dosage of water, decocting time, the screening for decocting number
Experimental method: weighing above each medicine materical crude slice by formula, and totally nine parts, the water of phase application amount is added by L9 (34) orthogonal arrage 2, And it is tested by orthogonal arrage 3 is orthogonal.Extracting solution filtration, merges, and is concentrated under reduced pressure, is transferred in the measuring bottle of 100ml, and fixed with water Hold to scale.Measure the rate of extract.It the results are shown in Table 3, variance analysis is shown in Table 4.
2 factor level table of table
It is horizontal Decoct number (secondary) A Dosage (times water) B of water Decocting time (h) C
1 1 1(10) 1
2 2 2(12) 1.5
3 3 3(15) 2
3 orthogonal experiments of table and intuitive analytical table
4 the rate of extract analysis of variance table of table
Soruces of variation Sum of square of deviations Freedom degree F ratio F critical value Conspicuousness
A 55.02 2 18.16 19 P > 0.05
B 4.58 2 1.51 19 P > 0.05
C 1.10 2 0.36 19 P > 0.05
As a result are as follows: ABC factor there are no significant difference considers that selective extraction condition is A2B2C1 from production cost is saved: It adds water to cook 2 times, every time plus 12 times of water are measured, and decocting 1 hour every time is extraction conditions.
3. orthogonal processing verification test
Each medicine materical crude slice is weighed by formula, totally three parts, is tested respectively according to preferred technique, decocting liquid filtration, filtrate merges, It is transferred in the measuring bottle of 250ml, water is added to be settled to scale.Measure the rate of extract.It the results are shown in Table 5.
5 orthogonal processing verification test result of table
Number The rate of extract (%)
1 16.8
2 16.9
3 17.0
Average value 16.9
Experimental result illustrates that the extraction process after optimization is feasible, and reproducibility is preferable.
4. material specific gravity
According to the extracting solution of selection process, it is concentrated into different specific gravity, it can be spray-dried recovery rate and actual production As a result row see the table below.
6 material specific gravity of table
The result shows that: concentration specific gravity is that the yield of 1.02-1.04 (60 DEG C) is high, therefore selecting concentration specific gravity is 1.02-1.04.
5. pilot scale research
It is exaggerated test by determining preparation process for the feasibility of verification test, is prepared for a collection of pilot extraction Object is detailed in following table.
The preparation of 7 pilot extraction object of table
Serial number Inventory (kg) Extract must measure (g) The rate of extract (%)
1 3.0 500 16.7
Clinical research experimental data:
One, object and method
(1) clinical data
1. case source
Choose from June, 2017 to during in November, 2018 in Lishui City institute of traditional Chinese medicine Cardiological, Neurology or Nephrology dept. It is medical, meet the hypertension syndrome of blood stasis for the standard of being included in target organ damage patient 64, is randomly divided into experimental group and control group is each 32.It is chosen simultaneously with period Lishui City institute of traditional Chinese medicine medical center physical examination healthy person 32 as healthy group.
2. diagnostic criteria
2.1 Diagnosing Hypertension standards
Evaluation of Diagnostic Criteria of Hypertension according to Chinese hypertension prevention and control guide revise the committee publication " Chinese hypertension prevention and control refers to South " revised edition was formulated 2010 years: in the case where antihypertensive drugs is not used, non-3 measurement blood pressures on the same day, systolic pressure >= 140mmHg and (or) diastolic pressure >=90mmHg person；Or previously have specific hypertension history, currently take antihypertensive drugs Person is also diagnosed as hypertension though blood pressure is lower than 140/90mmHg.
2.2 hypertension syndrome of blood stasis diagnostic criteria
Hypertension syndrome of blood stasis diagnostic criteria referring especially to issue within health ministry 2002 " new Chinese medicine clinical research refers to Lead principle ", and clinical practice experience is combined to formulate.
Primary symptom: 1. headache is as pierced, fixed pain；2. dizziness；3. uncomfortable in chest, pectoralgia, position are fixed；4. extremity numbness is inclined Paralysis；5. ecchymosis.
Minor symptom: 1. scaly dry skin, a symptom of blood stasis；2. dysmenorrhea has clot, amenorrhoea；3. amnesia；4. lip is purple dark；5. purplish tongue has the stasis of blood Point ecchymosis；6. uneven pulse or heavy string, string are slow.
Meet above-mentioned primary symptom 2 or primary symptom 1 and minor symptom 2 is i.e. diagnosable.
2.3 ventricular hypertrophy diagnostic criteria
The left ventricular hypertrophy diagnostic criteria that the present invention recommends according to Asia left ventricular hypertrophy Consensus of experts combination Color Sonography It formulates: the mark by left ventricular mass index (Left Ventricular Mass Index, LVMI) as diagnosis left ventricular hypertrophy Standard, i.e. LVMI >=125g/m2(male), >=120g/m2(female).Patient's diastole left room is measured with colorful Doppler ultrasound diagnostic apparatus Internal diameter (LVIDd), diastole chamber interval thickness (VSTd) and left ventricular posterior wall thickness (PWTd), by Devereux formula, i.e., the left heart Room weight LVM (g)=0.8 × 1.04 [(VSTd+LVIDd+PWTd)3-(LVIDd)3]+0.6；BSA is body surface area, BSA (m2) =0.0061 × height (cm)+0.0128 × weight (kg) -0.1529；LVMI(g/m2)=LVM (g)/BSA (m2)。
2.4 the standard of Renal Injury
It is micro- that current scholars most in the world think that 20 μ g/min or 3Omg/L total protein of urinary albumin excretion ratio > can be used as Measure the critical value of albuminuria.The present invention measures microdose urine protein (mALB) > 30mg/L using random urine immunoturbidimetry, And routine urinalysis protein urine is negative, blood urea nitrogen (Blood urea nitrogen, BUN), serum creatinine (Serum Creatinine, Scr) normal range (NR), the standard as Renal Injury.
2.5 arteria carotis damage standard
The evaluation criteria that middle film (Carotid Intima-Media Thickness, CIMT) thickens in arteria carotis is referring in " the vascular ultrasound guide " that ultrasonic doctor branch, doctors'associations, state promulgates: 1.0mm≤CIMT < 1.5mm.
3. being included in standard
Hypertension Patients with Blood Stasis Syndrome: 1. meet Evaluation of Diagnostic Criteria of Hypertension, and exclude secondary hypertension；
2. differential diagnosis in tcm meets the CM syndrome differentiation criterion of hypertension syndrome of blood stasis；
3. meeting the one of ventricular hypertrophy, Renal Injury and arteria carotis damage standard；
4. hypertensive disease was at 6 months or more；
5. the age between 40-70 years old, male or female；
Healthy group: the equal normal range (NR) of medical center physical examination indices, age between 20-35 years old, inquire in conjunction with medical history Person without exception.
4. exclusion criteria
1. not meeting and above-mentioned being included in standard；
2. simultaneously in above-mentioned target organ damage two target organ damages and the above person；
3. gestation or lactating female are not able to cooperate completion and grind to research drug allergy person, feeblemindedness or insanity The person of studying carefully；
4. being associated with serious hepatic and kidney function obstacle, New York Ⅲcardiac function or more, malignant tumour and hematological system etc. Related disease；
5. occurring in nearly half a year major cardiovascular events (acute myocardial infarction AMI, dissection of aorta, cerebral apoplexy etc.) and tight The heavy losses person that injures capital operation；
6. existing and taking calcium ion receptor antagonist and (or) beta-blocker contraindication person；
5. falling off and rejecting case standard
1. there is severe complication during treatment or the state of an illness deteriorating suddenly, it is necessary to urgent intervention measure influence be taken to grind immediately Study carefully normal development person；
2., using the drug shared or other treatments is forbidden, being influenced effectively not by research approach regulation drug user after being included in Property and safe sex determination person；
3. because personal inclination actively exits in therapeutic process, or cannot complete entirely to study treatment course, so that influencing to treat The case of effect, then be considered as and fall off；
4. because a variety of causes leads to the infull person of data.
(2) research method
1. group technology
To be collected into and meet above-mentioned hypertension syndrome of blood stasis with target organ damage patient 64, with SAS software in 1: 1 ratio into The random grouping of row, is randomly divided into experimental group (Western medicine+Chinese medicine) 32, control group (Western medicine) 32, and case once enters group must not be with Meaning change.
Phase physical examination healthy person 32 while another collection, it is included in healthy group.
2. therapeutic scheme
2.1 intervening measure
Control group: conventional hypertensive knowledge propaganda and education is carried out to patient, low-salt and low-fat diet is simultaneously discontinued the habit of smoking and drinking, blood pressure < 160/100mmHg person gives amlodipine besylate tablets 5mg (trade name: Amlodipine Besylate Tablet, specification: every 5mg, producer: Pfizer's system Medicine Co., Ltd) it takes orally once a day；Blood pressure >=160/100mmHg person gives amlodipine besylate tablets 5mg and takes orally daily one It is secondary, combine Metoprolol succinate sustained-release tablets 47.5mg (trade name: Betaloc, specification: every 47.5mg, producer: A Sili Health pharmaceutical Co. Ltd) it is oral, once a day.
Experimental group: on the basis of the treatment of above-mentioned control group, add with the She nationality, distributed over Fujian, Zhejiang, Jiangxi and Guangdong's medicine prescription, specific prescription and dosage regimen are as follows:
The She nationality, distributed over Fujian, Zhejiang, Jiangxi and Guangdong's medicine prescription composition: food 10 parts of herbal tea (Liu Yazi), 12 parts of loud, high-pitched sound dog Lu (harvest), 30 parts of Radix Salviae Miltiorrhizae, cortex moutan 15 Part, 12 parts of radix paeoniae rubra, 9 parts of Rhizoma Gastrodiae, 15 parts of uncaria, 15 parts of rhizoma acori graminei, 15 parts of radix cyathulae, scalds leech powder 1.5 at 30 parts of dry motherwort Part.
1. person adds with ventricular hypertrophy: 20 parts of Radix Astragali, 15 parts of raw hawthorn.
2. person adds with renal damage: 15 parts of RHIZOMA POLYGONATI PREPARATA, 30 parts of centella.
3. impairer adds with arteria carotis: 30 parts of pueraria lobata.
The preparation method of the She nationality, distributed over Fujian, Zhejiang, Jiangxi and Guangdong's medicine prescription, comprising the following steps:
(1) by weight, by 12 parts of loud, high-pitched sound dog Lu, 30 parts of Radix Salviae Miltiorrhizae, 15 parts of cortex moutan, 30 parts of dry motherwort, 12 parts of radix paeoniae rubra, 9 parts of Rhizoma Gastrodiae, 15 parts of radix cyathulae；
1. person adds with ventricular hypertrophy: 20 parts of Radix Astragali, 15 parts of raw hawthorn；
2. person adds with renal damage: 15 parts of RHIZOMA POLYGONATI PREPARATA, 30 parts of centella；
3. impairer adds with arteria carotis: 30 parts of pueraria lobata；
The water that 12 times of weight are added decocts 1-2h, filtering, and medical fluid is retained.
(2) 4 times of amount water are continuously added in the dregs of a decoction of step (1), food 10 parts of herbal tea, 15 parts of uncaria, stone Chang is added in decocting 1h 15 parts of Pu, continue to decoct 20 minutes, filtering, medical fluid merges with step (1) Chinese medicine liquid；
(3) medical fluid of step (2) carries out being concentrated into concentrate relative density being 1.03, pH value 5.1；
(4) 1-2 parts of leech powder is scalded, merges with step (3) Chinese medicine liquid, obtains the She nationality, distributed over Fujian, Zhejiang, Jiangxi and Guangdong's medicine prescription.
Instructions of taking: each 20ml, three times a day.
Experimental group and treatment group's treatment course are 16 weeks.
3. monitoring index
3.1 hypertension syndrome of blood stasis are with its gender of target organ damage patient Regular, age, the course of disease, weight, height, cigarette The past medical histories such as wine history, diabetes and the general information such as take drugs at this stage.
3.2 measurement experiment groups and the pretherapy and post-treatment blood pressure level of control group auscultate Korotkoff's Sound with standard desktop mercurial sphygmomanometer Method measures subject to Clinical blood pressure, and concrete operations scheme is carried out in strict accordance with Chinese blood pressure measurement guide related request.
3.2 routine monitoring vital sign patients (body temperature, breathing, pulse, blood pressure), three big routine, hepatic and renal function, blood glucose blood Rouge, Color Sonography and electrocardiogram etc..
Whether there is or not discomforts, such as dizziness headache, gas-tight, pectoralgia palpitaition uncomfortable in chest, nausea to vomit by regular follow-up patient in 3.3 therapeutic process It spits.If any generation, treatment measures should be actively taken, and are recorded in adverse reaction record sheet in detail.
4. blood vessel inner skin cell function detects
4.1 serum collection
The serum collection time: 1 day acquisition venous blood after experimental group and control group before the treatment 1 day and treatment end； Healthy group acquires venous blood the next morning after screening is qualified.Three groups of samples are both needed to 8 hours or more on an empty stomach, Yu Qingchen 7- 9 point empty stomach venous blood samples, be statically placed in it is dry without cingula cap without in anticoagulant test tube, after blood self-solidifying under the conditions of 4 DEG C, with 2000 rpms, 15 minutes (4 DEG C, 2000rpm, 15min) are centrifuged, take upper serum to be placed in sterile EP tube, water bath with thermostatic control 56 DEG C of case water-bath 30 minutes inactivation, and be placed on -20 DEG C of refrigerators and freeze, it is spare.Serum for In vitro cell experiment is respectively The pooled serum of each group case different periods.
4.2 vascular endothelial cell strain sources
This experiment human umbilical vein cell strain (ECV-304) used is by Wuhan University " China typical culture collection center " It provides.
4.3 human umbilical vein cell culture and intervention
Human umbilical vein endothelial (ECV-304) is inoculated in sterile culture flask, 37 DEG C, 5%CO are placed in2And saturation It is cultivated in humidified incubator, its growth fusion situation is observed under inverted phase contrast microscope, and regularly replace culture solution, to it It when merging in blocks and confluent cultures bottle 70-80%, is timely seeded in new culture bottle, carries out cell and pass on Multiplying culture, So that test experience uses below.The Human umbilical vein endothelial cells for selecting 3-7 generation and the logarithmic phase growth period of being in, use tryptose After enzymic digestion, single cell suspension is made with containing the fetal calf serum culture medium after 10% inactivation, takes a little single cell suspension blood Cell counting board counts, and calculates total number of cells, final adjustment is that cell concentration is 5*104/ ml, then with the mark in the hole 200ul/ Standard is inoculated in 96 well culture plates.Place it in 37 DEG C, 5%CO2And no blood is changed into after cultivating 24 hours in saturated humidity incubator Clear culture solution continues culture 24 hours, and synchronizing processing is then used respectively containing 10% healthy group or experimental group, control group Different time points (before treatment, after treatment) serum free culture system liquid (10% patients serum+90%RPMI) continues to train under the same conditions It supports 24 hours, every group of 7 multiple holes are changed serum-free medium and cultivated again 24 hours with phosphate-buffered salt water washing 3 times of preparation Afterwards, take culture plate supernatant for detecting.
4.4 different index detection methods
Imbalance method, thromboxane element and 6- ketone forefront are used in nitric oxide detection nitrate reductase method, endothelin -1 detection - 1 α of parathyrine, which is detected, uses radioimmunology, and all detecting steps are carried out in strict accordance with kit operation instruction in the present invention.
(3) it statisticallys analyze
, the measurement data for statistical analysis to experimental data using SPSS20.0 software package, meet normal distribution and Substantially conform to the use average ± standard deviation form of normal distributionIndicate, the comparison between data using t inspection, it is non-just State distribution rank sum test, enumeration data use-case (%) i.e. n (%) form indicate that, using Chi-square Test, P < 0.05 has for difference Statistical significance.
Two, result of study
(1) two group of patient's general information comparison result
1. two groups of Genders, medication situation, personal history and past medical history compare
It is male 15, women 17, smoker 5, alcohol user 8, diabetic 10, single in experimental group patient With amlodipine besylate tablets Treatment of Hypertension 18, amlodipine besylate tablets joint Metoprolol succinate sustained-release tablets decompression is controlled Treat 14.Control group male 11, women 21, smoker 8, alcohol user 5, diabetic 8, benzene sulfonic acid ammonia is applied alone Flordipine piece Treatment of Hypertension 21, amlodipine besylate tablets combine Metoprolol succinate sustained-release tablets Treatment of Hypertension 11.Through There is (P > in gender, tobacco and wine history, diabetic history and antihypertensive drugs service condition no significant difference in statistical analysis, two groups of patients 0.05).See Table 1 for details.
Comparison sheet (n (%), n=32) of the 1 two groups of patients of table in gender, tobacco and wine history and diabetic history
Project Gender (male/female) It smokes (example (%)) Drink (example (%)) Diabetes (example (%)) Medication (single medicine/two medicines)
Experimental group 15/17 5 (15.6%) 8 (25.0%) 10 (31.2%) 18/14
Control group 11/21 8 (25.0%) 5 (15.6%) 8 (25.5%) 21/11
χ2Value 1.036 0.869 0.869 0.309 0.591
P value 0.309 0.351 0.351 0.578 0.442
Note: it single medicine: indicates only to use amlodipine besylate tablets Treatment of Hypertension, two medicines: indicating amlodipine besylate tablets connection Close Metoprolol succinate sustained-release tablets Treatment of Hypertension.
2. two groups of general measurement datas of patient compare
Experimental group average age 66.66 ± 11.99 years old, hypertensive disease 5.44 ± 3.04 years, body mass index 22.63 ± 1.05kg/m2.Control group average age 68.47 ± 10.58 years old, hypertensive disease 5.31 ± 2.89 years, body mass index 22.98 ± 1.16kg/m2, compared no difference of science of statistics (P > 0.05) between two groups of ages, the course of disease and body mass index.Analysis shows that experimental group With the general basic data such as blood glucose, blood lipid, renal function and the homocysteine of control group without obvious statistical difference (P > 0.05).See Table 2 for details.
2 two groups of patient's measurement data comparison sheets of table
3. blood pressure level compares before two groups of patients treat
Experimental group average systolic is 154.69 ± 13.94mmHg before treating, and diastolic pressure is 94.69 ± 5.47mmHg；It is right It is 152.94 ± 12.11mmHg according to group average systolic, diastolic pressure is 93.56 ± 5.92mmHg, systolic pressure, diastolic pressure between two groups Though different, no difference of science of statistics (P > 0.05).See Table 3 for details.
Systolic pressure, diastolic pressure comparison sheet before 3 two groups of patients of table treat
Project SBP(mmHg) DBP(mmHg)
Experimental group 154.69±13.94 94.69±5.47
Control group 152.94±12.11 93.56±5.92
T value 0.536 1.491
P value 0.594 0.141
Target organ damage Indexes Comparison before 4. two groups of patients treat
With ventricular hypertrophy 12 in experimental group, 138.21 ± 18.56g/m of left ventricular mass index2, Renal Injury 11 Example, 182.14 ± 9.44mg/L of microalbumin, carotid artery intima thicken 9,1.34 ± 0.89mm of Carotic Intima-media Thinkness；It is right There are ventricular hypertrophy 11 according to association, 139.47 ± 19.19g/m of left ventricular mass index2, Renal Injury 11, Microalbunin White 181.61 ± 10.36mg/L, carotid artery intima thicken 10, Carotic Intima-media Thinkness 1.33 ± 0.91mm, target device between two groups Official's damage profile no difference of science of statistics (P > 0.05).See Table 4 for details, table 5.
Target organ distribution situation comparison sheet (n (%), n=32) before 4 two groups of patients of table treat
Target organ damage Indexes Comparison table before 5 two groups of patients of table treat
Project LVMI(g/m2) mALB(mg/L) CIMT(mm)
Experimental group 138.21±18.56 182.14±9.44 1.34±0.89
Control group 139.47±19.19 181.61±10.36 1.33±0.91
T value 0.483 0.645 0.641
P value 0.605 0.496 0.527
5. human umbilical vein endothelial passes on proliferation results.
As shown in Figure of description 1: attached drawing 1 is that the Human umbilical vein endothelial cells of secondary culture amplify 100 times of picture, warp Human umbilical vein endothelial (ECV-304) after culture, cell healthy growth, at shuttle shape, form is uniform, meets experiment needs.
6. blood vessel inner skin cell function compares three groups of samples before the treatment
Compared with healthy group, -1 α (6-Keto- of nitric oxide (NO) and 6- ketone prostaglandin of experimental group and control group PGF-1 α) there is apparent reduction, endothelin -1 (ET-1) and thromboxane plain (TXB2), which then have, significantly to be increased, and difference has system Meter learns meaning (P < 0.05).The equal no difference of science of statistics of NO, ET-1, TXB2 and 6-Keto-PGF-1 α between experimental group and control group group (P > 0.05).See Table 6 for details.
Blood vessel inner skin cell function comparison sheet before the different groups of table 6 are treated
Project NO(μmol/L) ET-1(pg/mL) TXB2(pg/mL) 6-Keto-PGF-1α(pg/mL)
Experimental group 40.79±6.94※# 176.15±15.02※# 368.23±68.49※# 21.42±4.31※#
Control group 41.57±6.77※ 178.29±13.64※ 371.53±76.81※ 20.37±5.17※
Healthy group 58.02±5.36 153.43±12.53 256.34±56.38 36.02±4.77
Note:※P < 0.05 compared with healthy group,#P > 0.05 is compared with the control group.
Each index of correlation compares (two) two groups of patients before and after treatment
1. the pretherapy and post-treatment systolic pressure of two groups of patients and diastolic pressure variation are compared
After treatment, experimental group systolic pressure is 134.13 ± 8.25mmHg, and diastolic pressure is 83.44 ± 5.68mmHg；Control group Systolic pressure is 138.88 ± 6.28mmHg, and diastolic pressure is 84.68 ± 5.83mmHg, the systolic pressure of experimental group and control group after treatment There is an apparent reduction before relatively treating with diastolic pressure, difference has statistical significance (P < 0.05), while by the blood pressure after treatment Discovery when comparison among groups is carried out, the experimental group systolic pressure after treatment has more obvious reduction compared with control group, and difference has system Meter learns meaning (P < 0.05), but the diastolic pressure no difference of science of statistics (P > 0.05) after treatment.See Table 7 for details.
The pretherapy and post-treatment blood pressure comparison sheet of 7 two groups of patients of table
Note:※P < 0.05 after treatment compared with control group,★P < 0.05 in pretherapy and post-treatment group compared with itself.
2. two groups of pretherapy and post-treatment changes of Nitric Oxide of patient compare
Experimental group and control group the patient nitric oxide level after treating have earlier above to be significantly risen, and has statistics before relatively treating Learn difference (P < 0.05), and after treating experimental group nitric oxide level be 52.66 ± 5.89 μm of ol/L compared with control group 47.17 ± 5.74 μm of ol/L, which have, further to be increased, and has statistical difference (P < 0.05).See Table 8 for details.
The pretherapy and post-treatment nitric oxide level comparison sheet of 8 two groups of patients of table
Project Before treatment (μm ol/L) After treatment (μm ol/L)
Experimental group 40.79±6.94 52.66±5.89※★
Control group 41.57±6.77 47.17±5.74★
Note:※P < 0.05 after treatment compared with control group,★P < 0.05 in pretherapy and post-treatment group compared with itself.
3. the pretherapy and post-treatment endothelin -1 variation of two groups of patients is compared
After treatment, the endothelin-1 level of two groups of patients has reduction, the statistically significant (P of difference before relatively treating < 0.05), endothelin-1 level is 165.54 ± 14.3pg/mL after experimental group treatment, compared with 171.02 ± 13.17pg/ of control group ML has significant decrease, and difference is statistically significant (P < 0.05).See Table 9 for details.
The pretherapy and post-treatment endothelin-1 level comparison sheet of 9 two groups of patients of table
Project Before treatment (pg/mL) After treatment (pg/mL)
Experimental group 176.15±15.02 165.54±14.31※★
Control group 178.29±13.64 171.02±13.17★
Note:※P < 0.05 after treatment compared with control group,★P < 0.05 in pretherapy and post-treatment group compared with itself.
4. the pretherapy and post-treatment thromboxane element variation of two groups of patients is compared
The thromboxane element level for treating rear experimental group and treatment group has apparent reduction, statistically significant (the P < of difference 0.05), thromboxane element comparison among groups discovery after the treatment, 287.88 ± 64.30pg/mL of experimental group is compared with control group 304.19 ± 66.39pg/mL is further decreased, and difference is statistically significant (P < 0.05).See Table 10 for details.
The horizontal comparison sheet of the pretherapy and post-treatment thromboxane element of 10 two groups of patients of table
Project Before treatment (pg/mL) After treatment (pg/mL)
Experimental group 368.23±68.49 287.88±64.30※★
Control group 371.53±76.81 304.19±66.39★
Note:※P < 0.05 after treatment compared with control group,★P < 0.05 in pretherapy and post-treatment group compared with itself.
5. pretherapy and post-treatment -1 α of the 6- ketone prostaglandin variation of two groups of patients is compared
- 1 alpha levels of experimental group and control group 6- ketone prostaglandin, have after treatment and increase, only in experimental group group after treatment 26.18 ± 4.60pg/mL, which relatively tests preceding 21.42 ± 4.31pg/mL, statistical difference (P < 0.05), though comparison among groups have not Together, but no difference of science of statistics (P > 0.05).See Table 1 for details 1.
Pretherapy and post-treatment -1 alpha levels comparison sheet of 6- ketone prostaglandin of 11 two groups of patients of table
Note:※P > 0.05 after treatment compared with control group,★P < 0.05 in pretherapy and post-treatment group compared with itself.
(3) two groups of patient safety Indexs measure results
In process of the present invention, case vital sign, three big routine, hepatic and renal function, blood pressure and blood lipoid, Color Sonography and the hearts are studied Electrograph etc. does not occur obvious exception, also occurs without significant discomfort symptom, this She nationality, distributed over Fujian, Zhejiang, Jiangxi and Guangdong medicine prescription is prompted to have preferable clinical safety.
The She nationality, distributed over Fujian, Zhejiang, Jiangxi and Guangdong's medicine prescription is to hypertension syndrome of blood stasis with the influence of target organ damage patients' blood
The present invention follows Hypertension Guideline and basic decompression principle, gives single medicine and joint Treatment of Hypertension scheme respectively, with Phase blood pressure preferably controls.Experimental group is given in control group scheme plus to the She nationality, distributed over Fujian, Zhejiang, Jiangxi and Guangdong's medicine prescription therapeutic, two in addition to Chinese medicine intervenes difference Group decompression scheme no difference of science of statistics (P > 0.05).The blood pressure of experimental group and control group has apparent reduction (P before relatively treating < 0.05), prompt two kinds of therapeutic schemes to have antihypertensive effect.Discovery when blood pressure compares between group after the treatment, the receipts of experimental group Contracting pressure is further reduced (P < 0.05), diastole compared with 138.88 ± 6.28mmHg of control group for 134.13 ± 8.25mmHg Though pressure also reduces, there is (P > 0.05) in no difference of science of statistics.Compared with the control group, experimental group blood pressure lowering effect is brighter It is aobvious, show that the She nationality, distributed over Fujian, Zhejiang, Jiangxi and Guangdong's medicine prescription in the present invention has the effect of assistance reduces blood pressure.
The She nationality, distributed over Fujian, Zhejiang, Jiangxi and Guangdong's medicine prescription influences vascular endothelial cell
Existing research shows that hypertension be one of initiating agent of vascular endothelial cell damage and its damage it is main One of factor.The mechanism of vascular endothelial cell damage caused by hypertension is complicated, not only with blood pressure level, blood pressure variability and machine Tool factor etc. is related, also with blood constituent change etc. factors it is related.There are some researches prove hypertensive patient's blood vessel inner skin cell functions With being incremented by for blood pressure level, endothelin -1, urinary albumin and creatinine ratio also significantly increase, and prompt vascular endothelial cell damage Hurt degree blood pressure level to be closely related.Blood Pressure Variability in Hypertensive patients increases, and can not only lead to blood vessel inner skin cell function It is impaired, and accelerate the formation of medial thickening and patch in arteria carotis on this basis.Blood Pressure of Patients with Essential Hypertension pathological state Increase, can to vascular endothelial cell generate it is mechanical drawing or shearing stimulate, cause the endocrine function of endothelial cell disorderly Disorderly, so that using ET-1, NO as the regulation of blood vessels factor proportional imbalance of representative, lead to vascular endothelium-dependent contraction and diastolic function It is not normal, and this will promote blood pressure further to increase.There is research and utilization syndrome of blood stasis cell model, with hypertension Patients with Blood Stasis Syndrome blood The clear human umbilical vein blood endothelial cell for intervening in vitro culture, discovery Serum of Patients with Hypertension can lead to blood vessel inner skin cell function Morphologic change is undermined, and Patients with Blood Stasis Syndrome damage is more serious.When hypertension causes vascular endothelial cell to be damaged, secretion Expansion angiogenic substance such as NO, prostaglandin excretion reduce, and vasoconstriction substance such as ET-1, TXA2 and angiotensins increase It is more.It is out of proportion that this will lead to activity regulating factor, so from vasoconstriction, accelerate atherosclerosis, promote platelet aggregation The number of ways such as collection further increase blood pressure or promote the formation of syndrome of blood stasis.Vascular endothelial cell and the close phase of cardiovascular disease It closes, and the variation of the indexs such as NO, ET-1 can reflect that blood vessel inner skin cell function changes, therefore the present invention is with blood pressure and function of vascular endothelium For focus, by the pretherapy and post-treatment blood pressure of observation and NO, ET-1,6-Keto-PGF-1 α, TXB2 level are detected, to evaluate Influence of this She nationality, distributed over Fujian, Zhejiang, Jiangxi and Guangdong medicine prescription therapeutic hypertension syndrome of blood stasis with the curative effect of target organ damage patient and to function of vascular endothelium.
It is a discovery of the invention that compared before treatment with health group, experimental group and control group NO, ET-1,6-Keto-PGF-1 α, TXB2 level has significantly different, ET-1 and TXB2 raising, NO, 6-Keto-PGF-1 α reduction, and difference all has statistical significance (P > 0.05).Confirm that hypertension blood Patients with Blood Stasis Syndrome serum has damaging action to vascular endothelial cell.It is depressured in the present invention simultaneously After treating 16 weeks, the index levels such as two groups of patients NO, ET-1, TXB2 have significant change before relatively treating, and have shown as statistics The NO for learning meaning increases, and ET-1, TXB2 reduce (P > 0.05).Experimental group can further increase NO on the basis of control, reduce ET-1, TXB2 (P > 0.05), and 6-Keto-PGF-1 α also there is statistical significance increase (P > 0.05).As mentioned before And this study found that activating blood and resolving stasis and treating play the role of decompression and protection blood vessel inner skin cell function.
Described before comprehensive, this She nationality, distributed over Fujian, Zhejiang, Jiangxi and Guangdong medicine prescription plays the role of decompression, particularly evident in terms of reducing systolic pressure, facilitates high blood Press Patients with Blood Stasis Syndrome controlling of blood pressure up to standard.Compared with healthy group, blood vessel endothelium of the hypertension syndrome of blood stasis with target organ damage patient Cell function is damaged.Vascular endothelial cell function of the hypertension syndrome of blood stasis with target organ damage patient after the She nationality, distributed over Fujian, Zhejiang, Jiangxi and Guangdong's medicine prescription therapeutic It can be improved earlier above.
Invention also provides a kind of production methods of invention, and the medical fluid after application production carries out clinical case Research, achieves preferable effect.Production method provided by the invention is easy to operate, feasible, applicability is wide, has as doctor The potential of institute's preparation further genralrlization.
The foregoing is merely presently preferred embodiments of the present invention, is not intended to restrict the invention, it is all in spirit of the invention and Within principle, made any modification, equivalent replacement, improvement etc. should all include within protection scope of the present invention.

Claims (3)

1. a kind of the She nationality, distributed over Fujian, Zhejiang, Jiangxi and Guangdong's medicine prescription for the treatment of hypertension syndrome of blood stasis, which is characterized in that the prescription is for hypertension syndrome of blood stasis With the Chinese prescription of medicine containing the She nationality, distributed over Fujian, Zhejiang, Jiangxi and Guangdong of target organ damage patient, by weight: including eating herbal tea 5-15 parts, 10-15 parts of loud, high-pitched sound dog Lu, Radix Salviae Miltiorrhizae 25-35 parts, 10-20 parts of cortex moutan, motherwort 25-35 parts dry, 10-15 parts of radix paeoniae rubra, 6-13 parts of Rhizoma Gastrodiae, 10-20 parts of uncaria, 10-20 parts of rhizoma acori graminei, scalds 1-2 parts of leech powder at 10-20 parts of radix cyathulae；
1. person adds with ventricular hypertrophy: 15-25 parts of Radix Astragali, 10-20 parts of raw hawthorn；
2. person adds with renal damage: 10-20 parts of RHIZOMA POLYGONATI PREPARATA, 25-35 parts of centella；
3. impairer adds with arteria carotis: 25-35 parts of pueraria lobata.
2. a kind of the She nationality, distributed over Fujian, Zhejiang, Jiangxi and Guangdong's medicine prescription for the treatment of hypertension syndrome of blood stasis as described in claim 1, which is characterized in that the prescription is pressed Poidometer: including eating 10 parts of herbal tea, 12 parts of loud, high-pitched sound dog Lu, 30 parts of Radix Salviae Miltiorrhizae, 15 parts of cortex moutan, 30 parts of dry motherwort, radix paeoniae rubra 12 Part, 15 parts of radix cyathulae, scalds 1.5 parts of leech powder at 9 parts of Rhizoma Gastrodiae, 15 parts of uncaria, 15 parts of rhizoma acori graminei；
1. person adds with ventricular hypertrophy: 20 parts of Radix Astragali, 15 parts of raw hawthorn；
2. person adds with renal damage: 15 parts of RHIZOMA POLYGONATI PREPARATA, 30 parts of centella；
3. impairer adds with arteria carotis: 30 parts of pueraria lobata.
3. a kind of the She nationality, distributed over Fujian, Zhejiang, Jiangxi and Guangdong's medicine prescription for the treatment of hypertension syndrome of blood stasis as claimed in claim 1 or 2, which is characterized in that described Food herbal tea be willow leaf calyx canthus, the loud, high-pitched sound dog Lu be harvest.
CN201910481381.2A 2019-06-04 2019-06-04 She medicine formula for treating hypertension blood stasis syndrome Active CN110179922B (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN201910481381.2A CN110179922B (en) 2019-06-04 2019-06-04 She medicine formula for treating hypertension blood stasis syndrome

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CN201910481381.2A CN110179922B (en) 2019-06-04 2019-06-04 She medicine formula for treating hypertension blood stasis syndrome

Publications (2)

Publication Number Publication Date
CN110179922A true CN110179922A (en) 2019-08-30
CN110179922B CN110179922B (en) 2021-03-16

Family

ID=67720200

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201910481381.2A Active CN110179922B (en) 2019-06-04 2019-06-04 She medicine formula for treating hypertension blood stasis syndrome

Country Status (1)

Country Link
CN (1) CN110179922B (en)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN114224924A (en) * 2021-12-22 2022-03-25 丽水市中医院 Application of herbal tea extract in preparation of medicine for reducing blood pressure and improving vascular remodeling
CN114504626A (en) * 2022-03-24 2022-05-17 丽水市中医院 She medicine formula for treating H-type hypertension phlegm-blood stasis syndrome

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20150190454A1 (en) * 2014-01-05 2015-07-09 Zhenbo Fan Herbal Composition and a Method for the Treatment of Qi Stagnancy and Blood Stasis Type of Hyperlipidemia

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20150190454A1 (en) * 2014-01-05 2015-07-09 Zhenbo Fan Herbal Composition and a Method for the Treatment of Qi Stagnancy and Blood Stasis Type of Hyperlipidemia

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
林祖辉 等: "消浊活血畲药治疗冠心病心绞痛合并高脂血症68例", 《浙江中医杂志》 *
潘铨 等: "畲药食凉茶组方结合西药治疗痰湿壅盛型原发性高血压30例", 《上海中医药杂志》 *

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN114224924A (en) * 2021-12-22 2022-03-25 丽水市中医院 Application of herbal tea extract in preparation of medicine for reducing blood pressure and improving vascular remodeling
CN114224924B (en) * 2021-12-22 2023-09-08 丽水市中医院 Application of herbal tea extract in preparation of antihypertensive drugs and drugs for improving vascular remodeling
CN114504626A (en) * 2022-03-24 2022-05-17 丽水市中医院 She medicine formula for treating H-type hypertension phlegm-blood stasis syndrome

Also Published As

Publication number Publication date
CN110179922B (en) 2021-03-16

Similar Documents

Publication Publication Date Title
CN110179922A (en) A kind of the She nationality, distributed over Fujian, Zhejiang, Jiangxi and Guangdong&#39;s medicine prescription for the treatment of hypertension syndrome of blood stasis
CN101856490A (en) Method for preparing Sini decoction granules from unprocessed radix aconiti lateralis
CN107744571A (en) A kind of pharmaceutical composition for improving blood vessel endothelium dysfunction and its production and use
Ibrahim et al. The Prevalence of Microalbuminuria in Type 2 Diabetes Mellitus Patients in Al-Husain Hospital in Karbala Province-Iraq
CN102319299B (en) Pharmaceutical composition for treating chronic renal failure and preparation method thereof
Azeez et al. Treatment response in adult patients with hypertension attending a secondary health care center in south-west Nigeria
Thaib et al. OVERVIEW OF FASTING BLOOD GLUCOSE LEVELS IN HYPERTENSION PUSHERS IN THE WORKING AREA OF PUSKESMAS, EAST CITY
CN102895485A (en) Traditional Chinese medicine composition for treating deficiency of kidney energy and blood stasis and preparation method of composition
Anchuelo et al. Prevalence, treatment and associated factors of hypertension in urban and rural areas of Spain
CN107029164A (en) A kind of pure Chinese medicine composition and pure Chinese medicinal preparation prepared therefrom for treating cognitive function attenuating
Calcaterra et al. AID-GM System (Advanced Intelligent Distant-Glucose Monitoring) to Monitor Health Status and Metabolic Control of Young People with Type 1 Diabetes
Akamo et al. The relationship between indices of hepatocellular injury and anthropometric measurements in some Babcock University Students, Ilisan, Ogun State, Nigeria
Cicero et al. INTERACTION BETWEEN LDL-CHOLESTEROLEMIA, SERUM URIC LEVEL AND INCIDENT HYPERTENSION: DATA FROM THE BRISIGHELLA HEART STUDY
Bonafini et al. Markers of arterial stiffness and subclinical vascular damages in obese children
Al-Said PP. 29.23: Global epidemiology of hypertension during the 21st century
CN109172731A (en) A kind of preparation method and applications of oyster compound extract that treating cough, essential hypertension and apoplexy
Wierzowiecka et al. Drug resistant hypertension and Munchausen syndrome
Salih et al. Undiagnosed Isolated Systolic Hypertension in Adult; Profile and Associated Factors
Yicheng Etiological Diagnosis of a Case of Hypertension
Lo et al. SUN-128 A CO-DESIGNED INTEGRATED DIABETES AND KIDNEY DISEASE MODEL OF CARE IMPROVES DIABETES SELF-CARE AMONG PATIENTS WITH COMORBID DIABETES AND KIDNEY DISEASE
Sato et al. [PP. 08.27] PREVALENCE AND CLINICAL BACKGROUND OF ATRIAL FIBRILLATION IN JAPANESE TYPE 2 DIABETES
CN104825526A (en) Traditional Chinese medicine composition for treating depression and preparation method, detection method and application thereof
Mutlu et al. Aortic knob width is associated with non-dipping blood pressure pattern
Shnain et al. Prevalence of Hypertension and Myocardial Infarction in Relation with Blood groups in Open Cardiac Center at Al-Najaf City.
CN110115728A (en) A kind of Chinese materia medica preparation and preparation method thereof for treating hypertension

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant